Home » Topics » BioWorld Science, Nephrology

BioWorld Science, Nephrology
RSS

Enrollment completed in phase II/III study of MN-001 in interstitial cystitis

Sep. 8, 2006

New agents for urinary incontinence disclosed in recent Norgine patent

Sep. 5, 2006

Novel therapeutic agents for nephrotoxicity developed at Hiroshima University

Sep. 4, 2006

New KCa channel activator a promising strategy for micturition control

Sep. 1, 2006

Gabapentin may be effective in treatment of neurogenic overactive bladder

Aug. 30, 2006

Novel agents for urological disorders disclosed in recent Dainippon Sumitomo patent

Aug. 29, 2006

Recent Janssen and Taiho patents describe new compounds for urological disorders

Aug. 16, 2006

Terlipressin fails to meet primary endpoint in type 1 hepatorenal syndrome study

Aug. 8, 2006

Phase IIb study planned for elocalcitol in overactive bladder

Aug. 1, 2006

German approval for new phosphate binding agent OsvaRen

July 25, 2006

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Circular RNA, the new beast in gene and cell therapy
BioWorld
Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
Advancing the 'best of both' – BMS, Hengrui enter $15.2B deal
BioWorld
In a deal potentially worth up to $15.2 billion, Jiangsu Hengrui Pharmaceuticals Co. Ltd. is joining efforts with Bristol Myers Squibb Co. to advance 13 early...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 12, 2026
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...